FDA clears ImaCor mini TEE probe, imaging system

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

ImaCor has received 510(k) clearance from the FDA to market the Zura imaging system and the ClariTEE probe, a miniaturized transesophageal echocardiography (TEE) probe which facilitates episodic monitoring of cardiac function.

The Uniondale, N.Y.-based ImaCor said its ClariTEE is a single-use device that can remain indwelling for up to 72 hours, allowing intensivists and anesthesiologists to periodically assess cardiac preload and left ventricular systolic function over a prolonged period of time.

“The ClariTEE probe is minimally invasive and allows physicians to directly visualize cardiac size and function, and to assess changes as pharmacologic interventions are made,” said Scott L. Roth, MD, CEO and a founder of ImaCor.